Kisqali (600 MG Dose) and Sodium Sulfate, Potassium Sulfate, and Magnesium Sulfate
Determining the interaction of Kisqali (600 MG Dose) and Sodium Sulfate, Potassium Sulfate, and Magnesium Sulfate and the possibility of their joint administration.
In the database of official manuals used in the service creation an interaction registered by statistical results of studies was found, which can either lead to negative consequences for the patient health or strengthen a mutual positive effect. A doctor should be consulted to address the issue of joint drug administration.
Consumer:Consumer information for this interaction is not currently available.MONITOR: The use of bowel cleansing preparations may increase the risk of ventricular arrhythmia, particularly torsade de pointes, in patients treated with drugs that prolong the QT interval. Severe and potentially fatal cases of electrolyte disorders and arrhythmias have been reported in elderly patients using bowel cleansing products. Electrolyte disturbances including hypokalemia and hypomagnesemia are known risk factors for torsade de pointes associated with QT interval prolongation. MANAGEMENT: Caution is advised when bowel cleansing preparations are prescribed in patients treated with drugs that prolong the QT interval. Monitoring of baseline and posttreatment serum electrolyte levels is recommended, particularly in the elderly. Patients should be instructed to drink plenty of clear liquids before, during, and after the bowel preparation process. Consideration should be given to consumption of 36 to 48 fluid ounces of a carbohydrate-electrolyte solution in the six hours before the first dose. Patients should be advised to seek prompt medical attention if they experience symptoms that could indicate the occurrence of torsade de pointes such as dizziness, lightheadedness, fainting, palpitation, irregular heart rhythm, shortness of breath, or syncope. References Cerner Multum, Inc. "Australian Product Information." O 0 Cerner Multum, Inc. "UK Summary of Product Characteristics." O 0 "Product Information. Suclear (polyethylene glycol 3350 with electrolytes)." Braintree Laboratories, Braintree, MA. "Product Information. Suprep Bowel Prep Kit (magnesium/potassium/sodium sulfates)." Braintree Laboratories, Braintree, MA. "Product Information. Fleet Phospho Soda (sodium biphosphate-sodium phosphate)." Fleet, CB, Lynchburg, VA. Hill AG, Parry BR "Hypokalaemia following bowel cleansing with sodium phosphate." N Z Med J 109 (1996): 347 "Product Information. Visicol (sodium biphosphate-sodium phosphate)." Salix Pharmaceuticals, Raleigh, NC. View all 7 references
Professional:MONITOR: The use of bowel cleansing preparations may increase the risk of ventricular arrhythmia, particularly torsade de pointes, in patients treated with drugs that prolong the QT interval. Severe and potentially fatal cases of electrolyte disorders and arrhythmias have been reported in elderly patients using bowel cleansing products. Electrolyte disturbances including hypokalemia and hypomagnesemia are known risk factors for torsade de pointes associated with QT interval prolongation.
MANAGEMENT: Caution is advised when bowel cleansing preparations are prescribed in patients treated with drugs that prolong the QT interval. Monitoring of baseline and posttreatment serum electrolyte levels is recommended, particularly in the elderly. Patients should be instructed to drink plenty of clear liquids before, during, and after the bowel preparation process. Consideration should be given to consumption of 36 to 48 fluid ounces of a carbohydrate-electrolyte solution in the six hours before the first dose. Patients should be advised to seek prompt medical attention if they experience symptoms that could indicate the occurrence of torsade de pointes such as dizziness, lightheadedness, fainting, palpitation, irregular heart rhythm, shortness of breath, or syncope.
- Cerner Multum, Inc. "Australian Product Information." O 0
- Cerner Multum, Inc. "UK Summary of Product Characteristics." O 0
- "Product Information. Suclear (polyethylene glycol 3350 with electrolytes)." Braintree Laboratories, Braintree, MA.
- "Product Information. Suprep Bowel Prep Kit (magnesium/potassium/sodium sulfates)." Braintree Laboratories, Braintree, MA.
- "Product Information. Fleet Phospho Soda (sodium biphosphate-sodium phosphate)." Fleet, CB, Lynchburg, VA.
- Hill AG, Parry BR "Hypokalaemia following bowel cleansing with sodium phosphate." N Z Med J 109 (1996): 347
- "Product Information. Visicol (sodium biphosphate-sodium phosphate)." Salix Pharmaceuticals, Raleigh, NC.
Generic Name: ribociclib
Brand name: Kisqali
Synonyms: Kisqali
Generic Name: magnesium sulfate / potassium sulfate / sodium sulfate
Brand name: Suprep Bowel Prep Kit
Synonyms: Magnesium sulfate, potassium sulfate, and sodium sulfate, Sodium Sulfate, Potassium Sulfate, Magnesium Sulfate Oral Solution
In the course of checking the drug compatibility and interactions, data from the following reference sources was used: Drugs.com, Rxlist.com, Webmd.com, Medscape.com.
- Kisqali (600 MG Dose)-Sodium Sulfate, Potassium Sulfate, Magnesium Sulfate Oral Solution
- Kisqali (600 MG Dose)-Sodium Sulfate, Potassium Sulfate, Magnesium Sulfate, and Polyethylene Glycol-Electrolyte Solution
- Kisqali (600 MG Dose)-Sodium Thiosulfate and Salicylic Acid
- Kisqali (600 MG Dose)-Sodium zirconium cyclosilicate
- Kisqali (600 MG Dose)-Sofosbuvir
- Kisqali (600 MG Dose)-Sofosbuvir and velpatasvir
- Sodium Sulfate, Potassium Sulfate, and Magnesium Sulfate-Kisqali Femara Co-Pack
- Sodium Sulfate, Potassium Sulfate, and Magnesium Sulfate-Kisqali Femara Co-Pack 200 mg-2.5 mg Dose
- Sodium Sulfate, Potassium Sulfate, and Magnesium Sulfate-Kisqali Femara Co-Pack 400 mg-2.5 mg Dose
- Sodium Sulfate, Potassium Sulfate, and Magnesium Sulfate-Kisqali Femara Co-Pack 600 mg-2.5 mg Dose
- Sodium Sulfate, Potassium Sulfate, and Magnesium Sulfate-Kitabis Pak
- Sodium Sulfate, Potassium Sulfate, and Magnesium Sulfate-Kitabis Pak inhalation